Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

A. Burger, Jan; M. Barr, Paul; Robak, Tadeusz; Owen, Carolyn; Ghia, Paolo; Tedeschi, Alessandra; Bairey, Osnat; Hillmen, Peter; Coutré, Steven; Devereux, Stephen; Grosicki, Sebastian; O. McCarthy, Helen; Simpson, David; Offner, Fritz; Moreno, Carol; Dai, Sandra; Lal, Indu; P. Dean, James; J. Kipps, Thomas

doi:10.1038/s41375-019-0602-x

Public

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Published in Leukemia • Oct 18, 2019

Authors:

Jan A. Burger

Paul M. Barr

Tadeusz Robak

Abstract

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5-0.8 mg/kg for ≤12 cycles. With a med...

Subject

Ibrutinib

Chlorambucil

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!